Follow-On Biologics Legislation Faces Tough Road Ahead; Momentum Stalled
Executive Summary
Prospects for enactment of follow-on biologics legislation appear limited in the near term, according to Capitol Hill players in the debate
You may also be interested in...
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
Follow-on Biologics: As Mark-Ups Loom, What's Waxman's End Game?
Coming to an abrupt halt after racing at full speed is never easy, but that seems to be the best play available to generic advocates of a legislative pathway for follow-on biologics
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].